In a recent Science paper, Sarel Fleishman et al. report the de-novo computational design of a protein interface to specifically target and tightly bind a surface patch of the flu hemaglutinin protein. We interview Sarel to get the insights from behind the scenes and the outlook for this exciting approach.
In a post yesterday on the Bleeding Edge Biotech Blog, Adam Kraut gives an expanded version of his article for Bio-IT World entitled Antibody Docking on the Amazon Cloud describing how Pfizer is leveraging the power and flexibility of cloud computing to run antibody docking simulations using Rosetta. Pfizer with help from the Rosetta Design Group (that’s us) developed an antibody modeling and docking workflow, which they then scaled up and tested on the cloud with help from BioTeam (which Kraut consults for and talks about in his post). This is a fascinating article and certainly the Pfizer/RDG/BioTeam/Rosetta/Amazon synergy is a phenomenon on the bleeding edge.